Darzalex Regimen May Improve MRD Responses in Multiple Myeloma - Cure Today
Adding Darzalex to VRd improved minimal-residual disease (MRD) responses and progression-free survival (PFS) in transplant-ineligible or -deferred newly diagnosed multiple myeloma patients, according to the phase 3 CEPHEUS trial. The overall MRD-negativity rate was 60.9% with Darzalex plus VRd versus 39.4% with VRd alone at 10^-5 sensitivity, and 46.2% versus 27.3% at 10^-6 sensitivity. The 54-month PFS rates were 68.1% and 49.5%, respectively, reducing the risk for disease progression or death by 43%. Darzalex also almost doubled the MRD-negative complete response rates sustained for more than 12, 24, and 36 months.
Highlighted Terms
Related News
Adding Darzalex to VRd improved minimal-residual disease (MRD) responses and progression-free survival (PFS) in transplant-ineligible or -deferred newly diagnosed multiple myeloma patients, according to the phase 3 CEPHEUS trial. The overall MRD-negativity rate was 60.9% with Darzalex plus VRd versus 39.4% with VRd alone at 10^-5 sensitivity, and 46.2% versus 27.3% at 10^-6 sensitivity. The 54-month PFS rates were 68.1% and 49.5%, respectively, reducing the risk for disease progression or death by 43%. Darzalex also almost doubled the MRD-negative complete response rates sustained for more than 12, 24, and 36 months.